BTT-T739 Orthotopic Mouse Model Service for Bladder Cancer

The BTT-T739 orthotopic mouse model represents a chemically induced, highly aggressive syngeneic bladder cancer platform that recapitulates muscle-invasive disease with documented visceral metastatic spread, offering a robust preclinical setting for evaluating intravesical agents and systemic anti-angiogenic compounds. Alfa Cytology leverages this T739-strain-matched system with optimized mucosal-injury implantation protocols, pathogen-free husbandry, and comprehensive endpoint histopathology to deliver reproducible tumor burdens and quantifiable metastatic indices tailored to your discovery program.

Overview of BTT-T739 Orthotopic Mouse Model for Bladder Cancer

BTT-T739 is a murine bladder transitional cell carcinoma line originally established from the urothelium of inbred T739 mice following chronic exposure to N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN), a potent tobacco-related bladder carcinogen. The resulting tumor displays a poorly differentiated, muscle-invasive phenotype with high-grade histological features that closely parallel the progression trajectory of human MIBC. When implanted orthotopically into the bladder lumen of syngeneic T739 hosts following controlled mucosal injury, BTT-T739 cells achieve a 100% tumor take rate and generate rapidly expanding luminal masses that invade the detrusor muscle within the first two to three weeks. The model is further distinguished by its propensity for spontaneous visceral metastasis—observed in approximately 23% of tumor-bearing animals to the liver, kidney, mesentery, and peritoneum—providing a rare preclinical window into the metastatic cascade of bladder cancer.

Fig 1. MRI/BLI multimodal imaging of an orthotopic model of bladder cancer. (Huebner, Doreen, et al., 2017)

Beyond its aggressive growth and metastatic behavior, BTT-T739 exhibits a pro-angiogenic molecular signature characterized by robust expression of vascular endothelial growth factor-A (VEGF-A), VEGF-C, and VEGFR-3, making it particularly relevant for anti-angiogenesis and lymphangiogenesis research. The model has also been engineered to express green fluorescent protein (BTT-T739-GFP), enabling direct fluorescence visualization of tumor margins, metastatic foci, and intravesical vector distribution without reliance on substrate-dependent imaging. These attributes collectively position BTT-T739 as a versatile tool for dissecting tumor-stromal interactions, testing novel intravesical delivery systems, and screening compounds targeting the VEGF axis in an immunocompetent, anatomically faithful bladder microenvironment.

Cell Line Information: BTT-T739

BTT-T739 is a well-characterized murine bladder carcinoma line with defined chemical origins, aggressive in vivo behavior, and documented metastatic potential. The table below summarizes its essential biological and technical parameters for preclinical study design.

Our Services

Alfa Cytology provides end-to-end BTT-T739 orthotopic model services encompassing cell-line authentication, mucosal-injury surgical implantation, longitudinal health monitoring, and terminal metastasis screening. Our team calibrates every inoculum density, preconditioning intensity, and endpoint criterion to your compound mechanism—whether you are interrogating anti-VEGF efficacy, intravesical drug penetration, or metastatic dissemination kinetics—ensuring datasets that withstand regulatory scrutiny and advance your pipeline with confidence.

Workflow of BTT-T739 Orthotopic Mouse Model Construction

Establishment of the BTT-T739 orthotopic bladder tumor model hinges on precise mechanical preconditioning of the urothelial barrier to enable tumor cell adhesion, followed by controlled intravesical delivery and rigorous postoperative surveillance. The protocol below reflects optimized methodologies drawn from peer-reviewed preclinical literature.

1. Cell Preparation and Viability Assessment: BTT-T739 cells are expanded in RPMI 1640 complete medium and harvested during logarithmic growth phase. Cell viability is confirmed by trypan blue exclusion, with only suspensions exceeding 90% viability accepted for implantation. Cells are washed twice in phosphate-buffered saline (PBS) to remove residual serum, then resuspended at a concentration of 1×10⁸ cells/mL in sterile PBS or serum-free medium and maintained on ice until instillation.
2. Animal Preparation and Anesthesia: Female T739 mice, 4–6 weeks old and weighing 20–22 g, are acclimatized for a minimum of one week under SPF conditions. On the procedure day, general anesthesia is induced via intraperitoneal sodium pentobarbital at 60 mg/kg. Depth of anesthesia is verified by absence of the toe-pinch reflex. Ophthalmic ointment is applied to prevent corneal drying, and the mouse is positioned supine on a heated surgical surface.
3. Mechanical Mucosal Preconditioning: A 24-gauge venous retention needle casing is lubricated with liquid paraffin and inserted transurethrally into the bladder lumen. Residual urine is evacuated by gentle suprapubic pressure. The stylet—pre-bent at a 5° to 7° angle approximately 15 mm from the tip to create a rotation radius of 2.61–3.66 mm—is inserted through the casing and rotated five full turns to mechanically disrupt the urothelial barrier. The stylet is then withdrawn, leaving the casing in place for cell delivery.
4. Intravescial BTT-T739 Instillation: The prepared cell suspension (100 µL containing approximately 1×10⁷ cells) is injected immediately through the indwelling casing into the bladder lumen. The casing is then withdrawn, and the mouse is maintained in a supine position for several minutes to promote cell-mucosa contact. No external clamping is required given the volume and retention dynamics of the injured bladder wall.
5. Post-Instillation Recovery and Health Surveillance: Mice are placed in warmed recovery cages and monitored for return of righting reflex. Body weight, activity level, hydration status, and hematuria are recorded daily for the first 72 hours and thereafter every two days. Analgesia is provided according to institutional IACUC guidelines. Mice exhibiting >15% body-weight loss, persistent hematuria, or signs of urinary obstruction are flagged for veterinary assessment.
6. Longitudinal Tumor Monitoring: For BTT-T739-GFP cohorts, tumor growth and metastatic spread are tracked via non-invasive fluorescence imaging under appropriate excitation wavelengths, enabling visualization of primary bladder masses and early detection of abdominal metastatic foci. In standard BTT-T739 studies, tumor progression is inferred from body-weight trajectories, hematuria scoring, and palpable abdominal distension. Bladder wet weight and macroscopic metastasis counts are recorded at necropsy.
7. Endpoint Necropsy and Comprehensive Tissue Collection: Mice are euthanized upon reaching humane endpoints or protocol-defined timepoints. The bladder is excised, weighed, and inspected for tumor burden and muscle invasion. A systematic metastasis survey is conducted across the liver, kidneys, mesentery, peritoneum, lungs, and spleen. Tissues are processed for formalin-fixed paraffin-embedded (FFPE) histopathology, snap-frozen molecular extraction, and—where applicable—fluorescence microscopy or flow-cytometric immune profiling.

Fig 2. BTT-T739 Orthotopic Mouse Model construction workflow.

Case Study-BTT-T739 Orthotopic Mouse Model Development

In a recent preclinical collaboration, Alfa Cytology established a BTT-T739 orthotopic cohort to support a sponsor's anti-angiogenic intravesical therapy program targeting the VEGF-C/VEGFR-3 axis. Following standardized mechanical mucosal preconditioning and intravesical instillation, all animals developed palpable bladder tumors within the anticipated two-week window, with 20% of the cohort exhibiting macroscopic peritoneal and mesenteric metastatic deposits at terminal necropsy. The study design incorporated an intravesical BCG control arm, a low-molecular-weight VEGFR-3 inhibitor arm, and a combination arm pairing the inhibitor with systemic anti-PD-L1 blockade. Terminal analyses revealed treatment-dependent reductions in bladder tumor wet weight, diminished VEGF-C immunohistochemical staining intensity, and altered CD31⁺ microvessel density within the tumor stroma, yielding pharmacodynamic insights that informed the sponsor's subsequent formulation-optimization strategy.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your BTT-T739 orthotopic bladder cancer study provides access to a specialized preclinical platform where surgical expertise, strain-matched syngeneic modeling, and multi-modal endpoint analysis converge to accelerate therapeutic discovery.

• Proficiency in the drift-angle stylet mechanical preconditioning technique ensures consistent mucosal injury depth and reproducible 100% tumor take rates across replicate T739 cohorts.
• Strain-matched syngeneic modeling in immunocompetent T739 mice preserves endogenous tumor-immune interactions, enabling robust evaluation of immunotherapies and myeloid-targeting strategies.
• Documented metastatic potential (~23% visceral spread) supports preclinical investigation of anti-metastatic agents, adjuvant therapies, and post-surgical recurrence models.
• Availability of BTT-T739-GFP fluorescence tracking provides direct, substrate-free visualization of tumor margins and metastatic foci for real-time pharmacodynamic readouts.
• Integrated VEGF-pathway analytics—including IHC, ELISA, and RNA-based quantification—are offered as standard endpoint packages aligned with the line's pro-angiogenic molecular signature.
• All studies are conducted within SPF barrier facilities under IACUC-approved protocols, with comprehensive necropsy documentation and GLP-compatible data packages available.

Contact Us

If your preclinical bladder cancer program requires an aggressive, metastasis-capable orthotopic model with proven syngeneic fidelity and a well-defined pro-angiogenic profile, reach out to Alfa Cytology to explore how our BTT-T739 platform can advance your therapeutic candidates. Our scientific team is prepared to design a customized study architecture, calibrate endpoint matrices to your mechanism of action, and deliver a detailed project roadmap. Contact us today to initiate a conversation that moves your discovery from bench to translational readiness.

For research use only. Not intended for any clinical use.